Login Register Cart 0
Generic placeholder image

CNS & Neurological Disorders - Drug Targets

Editor-in-Chief

ISSN (Print): 1871-5273
ISSN (Online): 1996-3181

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Perspective

Role of G-Proteins and GPCR-Mediated Signalling in Neuropathophysiology

Author(s): Md. Mominur Rahman, Sadia Afsana Mim, Md. Rezaul Islam, Nasrin Sultana, Muniruddin Ahmed and Mohammad Amjad Kamal*

Volume 22, Issue 1, 2023

Published on: 09 June, 2022

Page: [2 - 5] Pages: 4

DOI: 10.2174/1871527321666220430142722

Abstract

G-protein-coupled receptors (GPCRs) are activated by manifold neurotransmitters, and their activation, in turn, evokes slow synaptic transmission. They are profoundly related to numerous psychiatric and neurological disorders such as schizophrenia and Parkinson's disease. The significant malady indications for GPCR modulators demonstrate a change towards obesity, diabetes, and Alzheimer's disease, while other central nervous system disorders persist highly represented. GPR52, GPR6, and GPR8 are recognised as orphan GPCRs, co-exist either with both the dopamine D2 and D1 receptors in neurons of the basal ganglia or with the dopamine D2 receptor alone, and recommend that between these orphan receptors, GPR52 has the maximum potential of being a therapeutic psychiatric receptor. Genetically modified creature models and molecular biological investigations have suggested that these improved GPCRs could be potential therapeutic psychiatric receptors. In this perspective, the role of molecular targets in GPCR-mediated signalling has been discussed that would be novel drug design and discovery options for a scientist to elaborate previous knowledge with modern techniques.

Keywords: Alzheimer's disease, G protein-coupled receptors, neuropathophysiology, psychiatric receptors, neurotransmitters, neurological disorders.

« Previous Next »
Graphical Abstract

[1]
Husted AS, Trauelsen M, Rudenko O, et al. GPCR-mediated signaling of metabolites. Cell Metab 2017; 25(4): 777-96.
[2]
Agulhon C, Petravicz J, McMullen AB, et al. What is the role of astrocyte calcium in neurophysiology? Neuron Cell Press 2008; 59(6): 932-46.
[http://dx.doi.org/10.1016/j.neuron.2008.09.004] [PMID: 18817732]
[3]
Khan SM, Sung JY, Hébert TE. Gβγ subunits-Different spaces, different faces J Pharma Res 2016; 111: 434-41.
[http://dx.doi.org/10.1016/j.phrs.2016.06.026] [PMID: 27378564]
[4]
Bologna Z, Teoh JP, Bayoumi AS, Tang Y, Kim IM. Biased g protein-coupled receptor signaling: New player in modulating physiology and pathology. Biomol Ther (Seoul) 2017; 25(1): 12-25.
[http://dx.doi.org/10.4062/biomolther.2016.165] [PMID: 28035079]
[5]
Rahman MM, Ferdous KS, Ahmed M, et al. Hutchinson-gilford progeria syndrome: An overview of the molecular mechanism, pathophysiology and therapeutic approach. Curr Gene Ther Bentham Science Publishers Ltd 2021; 21(3): 216-29.
[http://dx.doi.org/10.2174/1566523221666210303100805] [PMID: 33655857]
[6]
Goldberg D, Steele JJ, Johnson A, Smith C. Ability of primary care physicians to make accurate ratings of psychiatric symptoms. Arch Gen Psychiatry 1982; 39(7): 829-33.
[http://dx.doi.org/10.1001/archpsyc.1982.04290070059011] [PMID: 7165481]
[7]
Kessler LG, Cleary PD, Burke JD Jr. Psychiatric disorders in primary care. Results of a follow-up study. Arch Gen Psychiatry 1985; 42(6): 583-7.
[http://dx.doi.org/10.1001/archpsyc.1985.01790290065007] [PMID: 4004500]
[8]
Jefferson JW. Treating affective disorders in the presence of cardiovascular disease. Psychiatr Clin North Am 1983; 6(1): 141-55.
[http://dx.doi.org/10.1016/S0193-953X(18)30845-1] [PMID: 6889170]
[9]
Cassileth BR, Lusk EJ, Strouse TB, et al. Psychosocial status in chronic illness. N Engl J Med Massachusetts Med Soc 1984; 311(8): 506-11.
[10]
Rahman MM, Islam MR, Islam MT, et al. Stem cell transplantation therapy and neurological disorders: Current status and future perspectives. Biology 2022; 11(1): 147.
[11]
Rahman MM, Rahaman MS, Islam MR, et al. Role of phenolic compounds in human disease: Current knowledge and future prospects. Molecules 2021; 27(1): 233.
[12]
Nichols DE. Hallucinogens. Pharmacol Ther 2004; 101(2): 131-81.
[http://dx.doi.org/10.1016/j.pharmthera.2003.11.002] [PMID: 14761703]
[13]
Thomas K, Malcolm B, Lastra D. Psilocybin-assisted therapy: A review of a novel treatment for psychiatric disorders. J Psychoactive Drugs Routledge 2017; 49(5): 446-55.
[http://dx.doi.org/10.1080/02791072.2017.1320734] [PMID: 28481178]
[14]
Newton DF, Naiberg MR, Goldstein BI. Oxidative stress and cognition amongst adults without dementia or stroke: Implications for mechanistic and therapeutic research in psychiatric disorders. Psychiatry Res 2015; 227(2-3): 127-34.
[http://dx.doi.org/10.1016/j.psychres.2015.03.038] [PMID: 25892258]
[15]
Dringen R, Hirrlinger J. Glutathione pathways in the brain. Biol Chem 2003; 384(4): 505-16.
[http://dx.doi.org/10.1515/BC.2003.059] [PMID: 12751781]
[16]
Halliwell B. Role of free radicals in the neurodegenerative diseases: Therapeutic implications for antioxidant treatment. Drugs Aging 2001; 18(9): 685-716.
[http://dx.doi.org/10.2165/00002512-200118090-00004]
[17]
Karry R, Klein E, Ben Shachar D. Mitochondrial complex I subunits expression is altered in schizophrenia: A postmortem study. Biol Psychiatry 2004; 55(7): 676-84.
[http://dx.doi.org/10.1016/j.biopsych.2003.12.012] [PMID: 15038995]
[18]
Chen L, Ding Y, Cagniard B, et al. Unregulated cytosolic dopamine causes neurodegeneration associated with oxidative stress in mice. J Neurosci 2008; 28(2): 425-33.
[http://dx.doi.org/10.1523/JNEUROSCI.3602-07.2008] [PMID: 18184785]
[19]
Larouche A, Berube P, Sarret P, Grignon S. Subacute H2O2, but not poly(IC), upregulates dopamine D2 receptors in retinoic acid differentiated SH-SY5Y neuroblastoma. Synapse 2008; 62(1): 70-3.
[http://dx.doi.org/10.1002/syn.20458] [PMID: 17960767]
[20]
Jia Z, Zhu H, Misra BR, Li Y, Misra HP. Dopamine as a potent inducer of cellular glutathione and NAD(P)H:quinone oxidoreductase 1 in PC12 neuronal cells: A potential adaptive mechanism for dopaminergic neuroprotection. Neurochem Res 2008; 33(11): 2197-205.
[http://dx.doi.org/10.1007/s11064-008-9670-4] [PMID: 18368484]
[21]
Dean O, Giorlando F, Berk M. N-acetylcysteine in psychiatry: Current therapeutic evidence and potential mechanisms of action. J Psychiatry Neurosci 2011; 36(2): 78-86.
[22]
Racz R, Sweet BV, Sohoni P. Oral acetylcysteine for neuropsychiatric disorders. Am J Heal Pharm Am Soc Health-Systems Pharm 2015; 72(11): 923-6. 928-929.
[http://dx.doi.org/10.2146/ajhp140732] [PMID: 25987686]
[23]
Ooi SL, Green R, Pak SC. N-Acetylcysteine for the treatment of psychiatric disorders: A review of current evidence. BioMed Res Int 2018; 2018: 2469486.
[24]
Krystal JH, State MW. Psychiatric disorders: Diagnosis to therapy. Cell 2014; 157(1): 201-14.
[PMID: 24679536]

Rights & Permissions Print Cite
Article Metrics
56
5
World Chronic Fatigue Syndrome Awareness Day
© 2024 Bentham Science Publishers | Privacy Policy